DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or α-hydroxytoremifene

Chemical Research in Toxicology

Volumn 20, Issue 2, 2007, Pages 300-310

  Da Costa, Gonçalo Gamboa ^a,b   Pereira, Pedro C ^a   Churchwell, Mona I ^b   Beland, Frederick A ^b   Marques, M Matilde ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (DEOXYGUANOSIN N 2 YL)TOREMIFENE; ALPHA HYDROXYTOREMIFENE; ALPHA SULFOXYTOREMIFENE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG SYNTHESIS; FEMALE; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; ISOTOPE LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SULFATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM; TAMOXIFEN; TOREMIFENE;

RATTUS;

EID: 33947160165     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx600275d     Document Type: Article

References (85)

1. Early Breast Cancer Trialists' Collaborative Group. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467.
2. Veronesi, U., Maisonneuve, P., Sacchini, V., Rotmensz, N., Boyle, P., and the Italian Tamoxifen Study Group. (2002) Tamoxifen for breast cancer among hysterectomised women. Lancet 359, 1122-1124.
3. IBIS Investigators. (2002) First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 360, 817-824.
4. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., and Boyle, P. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300.
5. Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., Runowicz, C. D., James, J. M., Ford, L. G., and Wolmark, N. (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 97, 1652-1662.
6. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., and Wilking, N. for the Stockholm Breast Cancer Study Group. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Cancer Inst. 87, 645-651.
7. Mignotte, H., Lasset, C., Bonadona, V., Lesur, A., Luporsi, E., Rodier, J.-F., Cutuli, B., Lasry, S., Mauriac, L., Granon, C., Kerr, C., Giard, S., Hill, C., de Lafontan, B., de Gislain, C., D'Anjou, J., Fondrinier, E., Lefeuvre, C., Parache, R.-M., and Chauvin, F. on behalf of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC). (1998) Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int. J. Cancer 76, 325-330.
8. Bernstein, L., Deapen, D., Cerhan, J. R., Schwartz, S. M., Liff, J., McGann-Maloney, E., Perlman, J. A., and Ford, L. (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl Cancer Inst. 91, 1654-1662.
9. Bergman, L., Beelen, M. L. R., Gallee, M. P. W., Hollema, H., Benraadt, J., van Leeuwen, F. E., and the Comprehensive Cancer Centres' ALERT Group. (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356, 881-887.
10. Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R., and Col, N. F. (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med. 18, 937-947.
11. Swerdlow, A. J., and Jones, M. E. for the British Tamoxifen Second Cancer Study Group. (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J. Natl. Cancer Inst. 97, 375-384.
12. Phillips, D. H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis 22, 839-849.
13. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9, 443-456.
14. Branham, W. S., Fishman, R., Streck, R. D., Medlock, K. L., DeGeorge, J. J., and Sheehan, D. M. (1996) ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity. Biol. Reprod. 54, 160-167.
15. Schwartz, L. B., Krey, L., Demopoulos, R., Goldstein, S. R., Nachtigall, L. E., and Mittal, K. (1997) Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am. J. Obstet. Gynecol. 176, 129-137.
16. Elkas, J., Armstrong, A., Pohl, J., Cuttitta, F., Martínez, A., and Gray, K. (2000) Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen. Obstet. Gynecol. 95, 697-703.
17. Karck, U., and Kommoss, F. (2000) Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast? Eur. J. Cancer 36, S45-S46.
18. Wilder, J. L., Shajahan, S., Khattar, N. H., Wilder, D. M., Yin, J., Rushing, R. S., Beaven, R., Kaetzel, C., Ueland, F. R., van Nagell, J. R., Kryscio, R. J., and Lele, S. M. (2004) Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone; a case controlled study. Gynecol. Oncol. 92, 553-558.
19. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res. 59, 2091-2095.
20. Tomás, E., Kauppila, A., Blanco, G., Apaja-Sarkkinen, M., and Laatikainen, T. (1995) Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol. 59, 261-266.
21. Wiseman, L. R., and Goa, K. L. (1997) Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 54, 141-160.
22. Marttunen, M. B., Hietanen, P., Tiitinen, A., and Ylikorkala, O. (1998) Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 83, 1158-1162.
23. Mäenpää, J., Holli, K., and Pasanen, T. (2000) Toremifene: where do we stand? Eur. J. Cancer 36, S61-S62.
24. Harvey, H. A., Kimura, M., and Hajba, A. (2006) Toremifene: an evaluation of its safety profile. The Breast 15, 142-157.
25. Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Mailliard, J. A., Jones, S. E., Vogel, C. L., Berris, R. F., Shemano, I., and Schoenfelder, J. (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 13, 2556-2566.
26. Gershanovich, M., Garin, A., Baltina, D., Kurvet, A., Kangas, L., Ellmén, J., and Eastern European Study Group. (1997) A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res. Treat. 45, 251-262.
27. Pyrhönen, S., Valavaara, R., Modig, H., Pawlicki, M., Pienkowski, T., Gundersen, S., Bauer, J., Westman, G., Lundgren, S., Blanco, G., Mella, O., Nilsson, I., Hietanen, T., Hindy, I., Vuorinen, J., and Hajba, A. (1997) Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br. J. Cancer 76, 270-277.
28. Pyrhönen, S., Ellmén, J., Vuorinen, J., Gershanovich, M., Tominaga, T., Kaufmann, M., and Hayes, D. F. (1999) Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat. 56, 133-143.
29. Holli, K., Valavaara, R., Blanco, G., Kataja, V., Hietanen, P., Flander, M., Pukkala, E., and Joensuu, H. for the Finnish Breast Cancer Group. (2000) Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J. Clin. Oncol. 18, 3487-3494.
30. Holli, K. on behalf of the Finnish Breast Cancer Group. (2002) Tamoxifen versus toremifene in the adjuvant treatment of breast cancer. Eur. J. Cancer 38, Supplement 6, S37-S38.
31. Milla-Santos, A., Milla, L., Rallo, L., and Solano, V. (2001) Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res. Treat. 65, 119-124.
32. Pagani, O., Gelber, S., Simoncini, E., Castiglione-Gertsch, M., Price, K., Zahrieh, D., Gelber, R., Coates, A., and Goldhirsch, A., International Breast Cancer Study Group. (2004) Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann. Oncol. 15, 1749-1759.
33. Price, D., Stein, B., Sieber, P., Tutrone, R., Bailen, J., Goluboff, E., Burzon, D., Bostwick, D., and Steiner, M. on behalf of the GTx-006-221 Study Team. (2006) Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIb clinical trial. J. Urol. 176, 965-971.
34. Sipilä, H., Kangas, L., Vuorilehto, L., Kalapudas, A., Eloranta, M., Södervall, M., Toivola, R., and Anttila, M. (1990) Metabolism of toremifene in the rat. J. Steroid Biochem. 36, 211-215.
35. Anttila, M., Valavaara, R., Kivinen, S., and Mäenpää, J. (1990) Pharmacokinetics of toremifene. J. Steroid Biochem. 36, 249-252.
36. Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J.-C., and Beaune, P. (1994) Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 47, 1883-1895.
37. Jones, R. M., and Lim, C. K. (2002) Toremifene metabolism in rat, mouse and human liver microsomes: Identification of α-hydroxytoremifene by LC-MS. Biomed. Chmmatogr. 16, 361-363.
38. Kim, S. Y., Suzuki, N., Laxmi, Y. R. S., Rieger, R., and Shibutani, S. (2003) α-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol. 16, 1138-1144.
39. Hashiba, M., Kasahara, T., Kim, S. Y., Shibutani, S., and Degawa, M. (2006) DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver. Cancer Sci. 97, 468-477.
40. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53, 4534-4541.
41. Hirsimäki, P., Hirsimäki, Y., Nieminen, L., and Payne, B. J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol. 67, 49-54.
42. Karlsson, S., Hirsimäki, Y., Mäntylä, E., Nieminen, L., Kangas, L., Hirsimäki, P., Perry, C. J., Mulhern, M., Millar, P., Handa, J., and Williams, G. M. (1996) A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem. Toxicol. 19, 245-266.
43. Williams, G. M., Iatropoulos, M. J., and Karlsson, S. (1997) Initiating activity of the anti-estrogen tamoxifen, but not toremifene in rat liver. Carcinogenesis 18, 2247-2253.
44. Kärki, A., Mäntylä, E., Hirsimäki, Y., Karlsson, S., Toikkanen, S., and Hirsimäki, P. (2000) Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis. Arch. Toxicol. 74, 249-256.
45. Dragan, Y. P., Vaughan, J., Jordan, V. C., and Pitot, H. C. (1995) Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16, 2733-2741.
46. Williams, G. M., Ross, P. M., Jeffrey, A. M., and Karlsson, S. (1998) Genotoxicity studies with the antiestrogen toremifene. Drug Chem. Toxicol. 21, 449-476.
47. Davies, R., Oreffo, V. I. C., Martin, E. A., Festing, M. F. W., White, I. N. H., Smith, L. L., and Styles, J. A. (1997) Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res. 57, 1288-1293.
48. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
49. Montandon, F., and Williams, G. M. (1994) Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch. Toxicol. 68, 272-275.
50. Hemminki, K., Widlak, P., and Hou, S.-M. (1995) DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16, 1661-1664.
51. Li, D., Dragan, Y., Jordan, V. C., Wang, M., and Pilot, H. C. (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 57, 1438-1441.
52. 14C]-radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem.-Biol. Interact. 106, 149-160.
53. Rajaniemi, H., Mäntylä, E., and Hemminki, K. (1998) DNA adduct formation by tamoxifen and structurally-related compounds in rat liver. Chem.-Biol. Interact. 113, 145-159.
54. Hellmann-Blumberg, U., Taras, T. L., Wurz, G. T., and DeGregorio, M. W. (2000) Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res. Treat. 60, 63-70.
55. Kim, S. Y., Suzuki, N., Laxmi, Y. R. S., Umemoto, A., Matsuda, T., and Shibutani, S. (2006) Antiestrogens and the formation of DNA damage in rats: a comparison. Chem. Res. Toxicol. 19, 852-858.
56. Shibutani, S., Ravindernath, A., Terashima, I., Suzuki, N., Laxmi, Y. R. S., Kanno, Y., Suzuki, M., Apak, T. I., Sheng, J. J., and Duffel, M. W. (2001) Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res. 61, 3925-3931.
57. Perrin, D. D., and Armarego, W. L. F. (1988) Purification of Laboratory Chemicals, 3rd. ed., pp 1-391, Pergamon, Oxford, U.K.
58. Heflich, R. H., Morris, S. M., Beranek, D. T., McGarrity, L. J., Chen. J. J., and Beland, F. A. (1986) Relationships between the DNA adducts and the mutations and sister-chromatid exchanges produced in Chinese hamster ovary cells by N-hydroxy-2-aminofluorene, N-hydroxy-N′- acetylbenzidine and 1-nitrosopyrene. Mutagenesis 1, 201-206.
59. Gamboa da Costa, G., Marques, M. M., Beland, F. A., Freeman, J. P., Churchwell, M. I., and Doerge, D. R. (2003) Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 16, 357-366.
60. Basler, J., Hastie, N. D., Pietras, D., Matsui, S.-I., Sandberg, A. A., and Berezney, R. (1981) Hybridization of nuclear matrix attached deoxyribonucleic acid fragments. Biochemistry 20, 6921-6929.
61. Beland, F. A., Fullerton, N. F., and Heflich, R. H. (1984) Rapid isolation, hydrolysis and chromatography of formaldehyde-modified DNA. J. Chromatogr. 308, 121-131.
62. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7, 1543-1551.
63. Gamboa da Costa, G., McDaniel-Hamilton, L. P., Heflich, R. H., Marques, M. M., and Beland, F. A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22, 1307-1315.
64. Foster, A. B., Jarman, M., Leung, O.-T., McCague, R., Leclercq, G., and Devleeschouwer, N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem. 28, 1491-1497.
65. Dasaradhi, L., and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol. 10, 189-196.
66. Gamboa da Costa, G., Hamilton, L. P., Beland, F. A., and Marques. M. M. (2000) Characterization of the major DNA adduct formed by α-hydroxy- N-desmethyltamoxifen in vitro and in vivo. Chem. Res. Toxicol. 13, 200-207.
67. Gamboa da Costa, G., Marques, M. M., Freeman, J. P., and Beland, F. A. (2003) Synthesis and investigation of α-hydroxy-N,N- didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen. Chem. Res. Toxicol. 16, 1090-1098.
68. Tessier, P. E., Penwell, A. J., Souza, F. E. S., and Fallis, A. G. (2003) (Z)-Tamoxifen and tetrasubstituted alkenes and dienes via a regio-and stereospecific three-component magnesium carbometalation palladium(0) cross-coupling strategy. Org. Lett. 5, 2989-2992.
69. Bedford, G. R., and Richardson, D. N. (1966) Preparation and identification of cis and trans isomers of a substituted triarylethylene. Nature 212, 733-734.
70. Richardson, A., Jr., Benson, H. D., and Hite, G. (1976) Stereochemistries of geometric isomers of 4-(2-bromo-1,2-diphenylvinyl)phenol. 4-(2-bromo-1,2-diphenylvinyl)anisole, and 2-[p-(2-bromo-1,2- diphenylvinyl)phenoxy]triethylamine: corrections of the literature. J. Pharm. Sci. 65, 1545-1547.
71. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L., and Phillips, D. H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56, 66-71.
72. Osborne, M. R., Hardcastle, I. R., and Phillips, D. H. (1997) Minor products of reaction of DNA with α-acetoxytamoxifen. Carcinogenesis 18, 539-543.
73. Kitagawa, M., Ravindernath, A., Suzuki, N., Rieger, R., Terashima, I., Umemoto, A., and Shibutani, S. (2000) Identification of tamoxifen-DNA adducts induced by α-acetoxy-N-desmethyltamoxifen. Chem. Res. Toxicol. 13, 761-769.
74. Marques, M. M., and Beland, F. A. (1997) Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 18, 1949-1954.
75. Kuramochi, H. (1996) Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J. Med. Chem. 39, 2877-2886.
76. Umemoto, A., Lin, C.-X., Ueyama, Y., Komaki, K., Laxmi, Y. R. S., and Shibutani, S. (2006) Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene. Chem. Res. Toxicol. 19, 421-425.
77. Bartsch, H., Phillips, D. H., Nair, J., Hewer, A., Meyberg-Solomeyer, G., and Grischke, E.-M. (2000) Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. Carcinogenesis 21, 845-847.
78. Beland, F. A., Marques, M. M., Gamboa da Costa, G., and Phillips, D. H. (2005) Letter to the editor. Tamoxifen-DNA adduct formation in human endometrium. Chem. Res. Toxicol. 18, 1507-1509.
79. Shibutani, S. (2005) Letter to the editor. Tamoxifen is a genotoxic carcinogen. Chem. Res. Toxicol. 18, 1509-1511.
80. Pukkala, E., Kyyrönen, P., Sankila, R., and Holli, K. (2002) Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int. J. Cancer 100, 337-341.
81. O'Regan, R. M., Cisneros, A., England, G. M., MacGregor, J. I., Muenzner, H. D., Assikis, V. J., Bilimoria, M. M., Piette, M., Dragan, Y. P., Pitot, H. C., Chatterton, R., and Jordan, V. C. (1998) Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 90, 1552-1558.
82. Marttunen, M. B., Cacciatore, B., Hietanen, P., Pyrhönen, S., Tiitinen, A., Wahlström, T., and Ylikorkala, O. (2001) Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br. J. Cancer 84, 897-902.
83. Hachisuga, T., Miyakawa, T., Tsujioka, H., Horiuchi, S., Emoto, M., and Kawarabayashi, T. (2003) K-ras mutation in tamoxifen-related endometrial polyps. Cancer 98, 1890-1897.
84. Hachisuga, T., Tsujioka, H., Horiuchi, S., Udou, T., Emoto, M., and Kawarabayashi, T. (2005) K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene. Br. J. Cancer 92, 1098-1103.
85. Wallén, M., Tomás, E., Visakorpi, T., Holli, K., and Mäenpää, J. (2005) Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother. Pharmacol. 55, 343-346.